Expression of p27 and p53 in cervical squamous cell carcinoma patients treated with radiotherapy alone: Radiotherapeutic effect and prognosis

Cancer

Volumn 88, Issue 12, 2000, Pages 2766-2773

  Oka, Kuniyuki ^a,b,c   Suzuki, Yoshiyuki ^a   Nakano, Takashi ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b Mito Saiseikai General Hospital   (Japan)

^c Mito Saiseikai General Hospital   (Japan)

Author keywords

Cervical squamous cell carcinoma; P27; P53; Prognosis; Radiotherapeutic effect; Radiotherapy

Indexed keywords

PROTEIN P27; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE S PHASE; CONTROLLED STUDY; EXON; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 0034660231     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000615)88:12<2766::AID-CNCR15>3.0.CO;2-G     Document Type: Article

References (42)

1. Polyak K, Lee H-M, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, et al. Cloning of p27KIP1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994;78:59-66.
2. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-4.
3. KIP1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. Cancer Res 1998;58:1042-7.
4. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997;57:3381-5.
5. KIP1 in multistage colorectal carcinogenesis. Cancer Res 1998;58: 114-22.
6. Kip1 expression independently predicts poor prognosis for patients with resectable pancreatic adenocarcinoma. Cancer 1999;85:1250-60.
7. Kip1 is a novel prognosis factors in localized human prostate adenocarcinoma. Cancer Res 1998;58: 542-8.
8. 1a,b) invasive breast carcinomas. Cancer Res 1997;57:1259-63.
9. Fredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, et al. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 1997;94:6380-5.
10. KIP1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-5.
11. KIP1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-30.
12. Kip1 in malignant melanoma. Inverse correlation with disease-free survival. Am J Pathol 1998;153:305-12.
13. Mineta H, Miura K, Suzuki I, Takebayashi S, Arnano H, Araki K, et al. Low p27 expression correlates with poor prognosis for patients with oral tongue squamous cell carcinoma. Cancer 1999;85:1011-7.
14. Lane DP. Cancer. A death in the life of p53. Nature 1993; 362:786-7.
15. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
16. Kainz C, Kohlberger P, Sliutz G, Breitenecker G, Reinthaller A. Mutant p53 in patients with invasive cervical cancer stages IB to IIB. Gynecol Oncol 1995;57:212-4.
17. Dellas A, Schultheiss E, Almendral AC, Gudat F, Oberholzer M, Feichter G, et al. Altered expression of mdm-2 and its association with p53 protein status, tumor-cell-proliferation rate and prognosis in cervical neoplasia. Int J Cancer 1997; 74:421-5.
18. Avall-Lundqvist EH, Silfversward C, Aspenblad U, Nilsson BR, Auer GU. The impact of tumor angiogenesis, p53 over-expression and proliferative activity (MIB-1) on survival in squamous cervical carcinoma. Eur J Cancer 1997;33:1799-804.
19. Oka K, Nakano T, Arai T. p53CM1 expression is not associated with prognosis in uterine cervical carcinoma. Cancer 1993;72:160-4.
20. Annual report on the results of treatment in carcinoma of the uterus, vagina and ovary. vol. 16. Radiumhemmet, Sweden: International Federation of Gynecology and Obstetrics, 1979.
21. Poulsen HE, Taylor CW, Sobin LH, Histological typing of female genital tract tumors. No. 13. Geneva: World Health Organization, 1975.
22. Arai T, Nakano T, Morita S, Sakashita K, Nakamura YK, Fukuhisa K. High-dose-rate remote afterloading intracavitary radiation therapy for cancer of the uterine cervix. A 20-year experience. Cancer 1992;69:175-80.
23. Oka K, Hoshi T, Nakano T, Arai T. Expression of human milk fat globule-1 in carcinomas of the uterine cervix treated with radiation therapy alone. Arch Pathol Lab Med 1992;116: 955-9.
24. Shi S-R, Key ME, Kalra K. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39: 741-8.
25. Murakami Y, Hayashi K, Hirohashi S, Sekiya T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res 1991;51: 5520-5.
26. Hollstein M, Sidransky D, Vogelstein B, Harris CC. P53 mutations in human cancers. Science 1991;253:49-53.
27. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989;5:874-9.
28. Hunt CR, Hale RJ, Buckley CH, Hunt J. p53 expression in carcinoma of the cervix. J Clin Pathol 1996;49:971-4.
29. Wilson GD, Richman PI, Dische S, Sanders MI, Robinson B, Daley FM, et al.. p53 status of head and neck cancer: relation to biological characteristics and outcome of radiotherapy. Br J Cancer 1995;71:1248-52.
30. Awwad S, Jaros E, Somes J, Lunec J. p53 overexpression in head and neck carcinoma and radiotherapy results. Int J Radiat Oncol Biol Phys 1996;34:323-32.
31. Raybaud-Diogene H, Fortin A, Morency R, Roy J, Monteil RA, Teru B. Markers of radioresistance in squamous cell carcinoma of the head and neck: a clinicopathologic and immunohistochemical study. J Clin Oncol 1997;15:1030-8.
32. Tatemoto Y, Osaki T, Yoneda K, Yamamoto T, Ueta E, Kimura T. Expression of p53 and p21 proteins in oral squamous cell carcinoma: correlation with lymph node metastasis and response to chemoradiotherapy. Pathol Res Pract 1998;194:821-30.
33. Niibe Y, Nakano T, Ohno T, Tsujii H, Oka K. Relationship between p21/WAF-1/CIP-1 and apoptosis in cervical cancer during radiation therapy. Int Radiat Oncol Biol Phys 1999; 44:297-303.
34. Siles S, Villalobos M, Valenzuela MT, Nunez MI, Gordon A, McMillan TJ, et al. Relationship between p53 status and radiosensitivity in human tumor cell lines. Br J Cancer 1996; 73:581-8.
35. Ku W-H, Liu I-L, Yen M-S, Chang Chien C-C, Yue C-T, Ma Y-Y, et al. Genomic deletion and p53 inactivation in cervical carcinoma. Int J Cancer 1997;72:270-6.
36. Milde-Langosch K, Albrecht K, Joram S, Schlechte H, Giessing M, Loning T. Presence and persistence of HPV infection and p53 mutation in cancer of the cervix uteri and the vulva. Int J Cancer 1995;63:639-45.
37. Helland Å, Holm R, Kristensen G, Kaern J, Karlsen F, Trope C, et al. Genetic alterations of the p53 gene, p53 protein expression and HPV infection in primary cervical carcinomas. J Pathol 1993;171:105-14.
38. Harima Y, Harima K, Shikata N, Oka A, Ohnishi T, Tanaka Y. Bax and Bcl-2 expressions predict response to radiotherapy in human cervical cancer. J Cancer Res Oncol 1998;124:503-10.
39. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993;75:495-505.
40. Huibregtse JM, Scheffner M, Howley PM. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol Cell Biol 1993;13:4918-27.
41. Stewart RL, Royds JA, Burton JL, Heatley MK, Wells M. Direct sequencing of the p53 gene shows absence of mutations in endometrial adenocarcinomas expressing p53 protein. Histopathology 1998;33:440-5.
42. Matsumoto T, Fujii T, Yabe M, Oka K, Hoshi T, Sato K. MIB-1 and p53 immunohistochemistry for differentiating pilocytic astrocytomas, and astrocytomas from anaplastic astrocytomas and glioblastomas in children and young adults. Histopathology 1998;33:446-52.